MC-vc-PAB-C6-a-amanitin

MC-vc-PAB-C6-a-amanitin Catalog number: BADC-00733

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

MC-vc-PAB-C6-a-amanitin is a drug-linker conjugate for ADC by using a-amanitin (a potent bicyclic octapeptide cytotoxin), linked via MC-vc-PAB-C6.

Category
ADCs Cytotoxin with Linkers
Product Name
MC-vc-PAB-C6-a-amanitin
Catalog Number
BADC-00733
Molecular Formula
C74H105N17O22S
Molecular Weight
1616.81
MC-vc-PAB-C6-a-amanitin

Ordering Information

Catalog Number Size Price Quantity
BADC-00733 -- $-- Inquiry
Description
MC-vc-PAB-C6-a-amanitin is a drug-linker conjugate for ADC by using a-amanitin (a potent bicyclic octapeptide cytotoxin), linked via MC-vc-PAB-C6.
Shipping
Room temperature
Storage
-20°C

MC-vc-PAB-C6-a-amanitin is a powerful peptide-drug conjugate (PDC) designed for targeted cancer therapy. The conjugate consists of the potent toxin a-amanitin, which is connected to a peptide via a cleavable valine-citrulline (vc) linker. This specific linker allows the drug to be activated selectively within the tumor environment, where enzymes cleave the linker and release a-amanitin directly into cancer cells. A-amanitin is known for its ability to inhibit RNA polymerase, leading to cell death. By targeting tumor cells while sparing healthy tissue, MC-vc-PAB-C6-a-amanitin minimizes systemic toxicity and enhances therapeutic efficacy.

Another critical application of MC-vc-PAB-C6-a-amanitin is in drug delivery optimization. The inclusion of the cleavable VC linker ensures that a-amanitin remains inactive during circulation, preventing off-target effects and toxicity to normal tissues. Once the conjugate reaches the tumor site, tumor-specific proteases cleave the linker, activating the drug within the cancer cell. This highly controlled release system enhances the therapeutic index by maintaining drug stability in the bloodstream and releasing the cytotoxic agent only where it is needed, resulting in more efficient and safer treatment.

MC-vc-PAB-C6-a-amanitin also shows potential in combination therapies for enhanced efficacy. When combined with other chemotherapeutic agents or immunotherapies, MC-vc-PAB-C6-a-amanitin can provide a synergistic effect. The targeted action of a-amanitin, which disrupts transcription in cancer cells, can be combined with the immune-modulating effects of immune checkpoint inhibitors or other chemotherapeutic agents to overcome resistance mechanisms and increase overall therapeutic response. This makes MC-vc-PAB-C6-a-amanitin a valuable tool in multi-drug treatment strategies.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Historical Records: DOXO-EMCH | MC-vc-PAB-C6-a-amanitin
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket